Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2011, Article ID 540148, 7 pages
http://dx.doi.org/10.1155/2011/540148
Review Article

Chemoprevention of Head and Neck Cancer by Green Tea Extract: EGCG—The Role of EGFR Signaling and “Lipid Raft”

1Department of Otorhinolaryngology and Head and Neck Surgery, Kyushu Koseinenkin Hospital, 2-1-1, Kishinoura, Nishiku, Kitakyushu 806-8501, Japan
2Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashiku, Fukuoka 812-8582, Japan
3Department of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan
4Deptartment of Pharmacology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan

Received 1 October 2010; Accepted 8 November 2010

Academic Editor: Pankaj Chaturvedi

Copyright © 2011 Muneyuki Masuda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. D. Hunter, E. K. Parkinson, and P. R. Harrison, “Profiling early head and neck cancer,” Nature Reviews Cancer, vol. 5, no. 2, pp. 127–135, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Corry, L. J. Peters, and D. Rischin, “Optimising the therapeutic ratio in head and neck cancer,” The Lancet Oncology, vol. 11, no. 3, pp. 287–291, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. D. I. Rosenthal, J. S. Lewin, and A. Eisbruch, “Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer,” Journal of Clinical Oncology, vol. 24, no. 17, pp. 2636–2643, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Machtay, J. Moughan, A. Trotti et al., “Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis,” Journal of Clinical Oncology, vol. 26, no. 21, pp. 3582–3589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Bernier, S. M. Bentzen, and J. B. Vermorken, “Molecular therapy in head and neck oncology,” Nature Reviews Clinical Oncology, vol. 6, no. 5, pp. 266–277, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. W. Kim, A. R.M.R. Amin, and D. M. Shin, “Chemoprevention of head and neck cancer with green tea polyphenols,” Cancer Prevention Research, vol. 3, no. 8, pp. 900–909, 2010. View at Publisher · View at Google Scholar
  7. C. S. Yang, X. Wang, G. Lu, and S. C. Picinich, “Cancer prevention by tea: animal studies, molecular mechanisms and human relevance,” Nature Reviews Cancer, vol. 9, no. 6, pp. 429–439, 2009. View at Google Scholar · View at Scopus
  8. C. S. Yang, L. Chen, M. J. Lee, D. Balentine, M. C. Kuo, and S. P. Schantz, “Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers,” Cancer Epidemiology Biomarkers and Prevention, vol. 7, no. 4, pp. 351–354, 1998. View at Google Scholar · View at Scopus
  9. H. H. S. Chow, Y. Cai, D. S. Alberts et al., “Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and Polyphenon E,” Cancer Epidemiology Biomarkers and Prevention, vol. 10, no. 1, pp. 53–58, 2001. View at Google Scholar · View at Scopus
  10. A. S. Tsao, D. Liu, J. Martin et al., “Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions,” Cancer Prevention Research, vol. 2, no. 11, pp. 931–941, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Shimizu, Y. Fukutomi, M. Ninomiya et al., “Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study,” Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 11, pp. 3020–3025, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Bettuzzi, M. Brausi, F. Rizzi, G. Castagnetti, G. Peracchia, and A. Corti, “Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study,” Cancer Research, vol. 66, no. 2, pp. 1234–1240, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. J. R. Grandis, M. F. Melhem, E. L. Barnes, and D. J. Tweardy, “Quantitative immunohistochemical analysis of transforming growth factor- α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck,” Cancer, vol. 78, no. 6, pp. 1284–1292, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. J. R. Grandis, M. F. Melhem, W. E. Gooding et al., “Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival,” Journal of the National Cancer Institute, vol. 90, no. 11, pp. 824–832, 1998. View at Google Scholar · View at Scopus
  15. S. Kalyankrishna and J. R. Grandis, “Epidermal growth factor receptor biology in head and neck cancer,” Journal of Clinical Oncology, vol. 24, no. 17, pp. 2666–2672, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. C. W. M. Reuter, M. A. Morgan, and A. Eckardt, “Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck,” British Journal of Cancer, vol. 96, no. 3, pp. 408–416, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Masuda, T. Wakasaki, M. Suzui, S. Toh, A. K. Joe, and I. B. Weinstein, “Stat3 orchestrates tumor development and progression: the Achilles' heel of head and neck cancers?” Current Cancer Drug Targets, vol. 10, no. 1, pp. 117–126, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Mrhalova, J. Plzak, J. Betka, and R. Kodet, “Epidermal growth factor receptor—its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas,” Neoplasma, vol. 52, no. 4, pp. 338–343, 2005. View at Google Scholar · View at Scopus
  19. M. T. Benchekroun, P. Saintigny, S. M. Thomas et al., “Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer,” Cancer Prevention Research, vol. 3, no. 7, pp. 800–809, 2010. View at Publisher · View at Google Scholar
  20. Q. Zhang, S. M. Thomas, S. Xi et al., “Src family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells,” Cancer Research, vol. 64, no. 17, pp. 6166–6173, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Willmore-Payne, J. A. Holden, and L. J. Layfield, “Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck,” Modern Pathology, vol. 19, no. 5, pp. 634–640, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. W. L. Jong, H. S. Young, Y. K. Su et al., “Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck,” Clinical Cancer Research, vol. 11, no. 8, pp. 2879–2882, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Hama, Y. Yuza, Y. Saito et al., “Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma,” Oncologist, vol. 14, no. 9, pp. 900–908, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. J. C. Sok, F. M. Coppelli, S. M. Thomas et al., “Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting,” Clinical Cancer Research, vol. 12, no. 17, pp. 5064–5073, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Yang, J. Chen, X. Zhang, and J. Cao, “Expression of Epidermal Growth Factor Receptor variant III in laryngeal carcinoma tissues,” Auris Nasus Larynx, vol. 36, no. 6, pp. 682–687, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Sorkin and L. K. Goh, “Endocytosis and intracellular trafficking of ErbBs,” Experimental cell research, vol. 315, no. 4, pp. 683–696, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Dikic, “CIN85/CMS family of adaptor molecules,” FEBS Letters, vol. 529, no. 1, pp. 110–115, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Wakasaki, M. Masuda, H. Niiro et al., “A critical role of c-Cbl-interacting protein of 85 kDa in the development and progression of head and neck squamous cell carcinomas through the Ras-ERK pathway,” Neoplasia, vol. 12, no. 10, pp. 789–796, 2010. View at Publisher · View at Google Scholar
  29. B. Rotblat, O. Yizhar, R. Haklai, U. Ashery, and Y. Kloog, “Ras and its signals diffuse through the cell on randomly moving nanoparticles,” Cancer Research, vol. 66, no. 4, pp. 1974–1981, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. U. C. Liang, S. Y. Lin-shiau, C. F. Chen, and J. K. Lin, “Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells,” Journal of Cellular Biochemistry, vol. 67, no. 1, pp. 55–65, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Masuda, M. Suzui, and I. B. Weinstein, “Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines,” Clinical Cancer Research, vol. 7, no. 12, pp. 4220–4229, 2001. View at Google Scholar · View at Scopus
  32. M. Masuda, M. Suzui, J. T. E. Lim, and I. B. Weinstein, “Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells,” Clinical Cancer Research, vol. 9, no. 9, pp. 3486–3491, 2003. View at Google Scholar · View at Scopus
  33. M. Masuda, M. Suzui, J. T. E. Lim, A. Deguchi, J. W. Soh, and I. B. Weinstein, “Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction,” Journal of Experimental Therapeutics and Oncology, vol. 2, no. 6, pp. 350–359, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Shimizu, A. Deguchi, Y. Hara, H. Moriwaki, and I. B. Weinstein, “EGCG inhibits activation of the insulin-like growth factor-1 receptor in human colon cancer cells,” Biochemical and Biophysical Research Communications, vol. 334, no. 3, pp. 947–953, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Shimizu, A. Deguchi, A. K. Joe, J. F. Mckoy, H. Moriwaki, and I. B. Weinstein, “EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells,” Journal of Experimental Therapeutics and Oncology, vol. 5, no. 1, pp. 69–78, 2005. View at Google Scholar · View at Scopus
  36. M. Shimizu, A. Deguchi, J. T. E. Lim, H. Moriwaki, L. Kopelovich, and I. B. Weinstein, “(-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells,” Clinical Cancer Research, vol. 11, no. 7, pp. 2735–2746, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Shimizu, Y. Shirakami, and H. Moriwaki, “Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG,” International Journal of Molecular Sciences, vol. 9, no. 6, pp. 1034–1049, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Shimizu, Y. Shirakami, H. Sakai et al., “(-)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells,” Chemico-Biological Interactions, vol. 185, no. 3, pp. 247–252, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Le Roy and J. L. Wrana, “Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling,” Nature Reviews Molecular Cell Biology, vol. 6, no. 2, pp. 112–126, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. S. K. Patra, “Dissecting lipid raft facilitated cell signaling pathways in cancer,” Biochimica et Biophysica Acta, vol. 1785, no. 2, pp. 182–206, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. P. Lajoie, J. G. Goetz, J. W. Dennis, and I. R. Nabi, “Lattices, rafts, and scaffolds: domain regulation of receptor signaling at the plasma membrane,” Journal of Cell Biology, vol. 185, no. 3, pp. 381–385, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Lingwood and K. Simons, “Lipid rafts as a membrane-organizing principle,” Science, vol. 327, no. 5961, pp. 46–50, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Adachi, T. Nagao, H. I. Ingolfsson et al., “The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells,” Cancer Research, vol. 67, no. 13, pp. 6493–6501, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Adachi, T. Nagao, S. To et al., “(-)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells,” Carcinogenesis, vol. 29, no. 10, pp. 1986–1993, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Adachi, M. Shimizu, Y. Shirakami et al., “(-)-Epigallocatechin gallate downregulates EGF receptor via phosphorylation at Ser1046/1047 by p38 MAPK in colon cancer cells,” Carcinogenesis, vol. 30, no. 9, pp. 1544–1552, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Tachibana, K. Koga, Y. Fujimura, and K. Yamada, “A receptor for green tea polyphenol EGCG,” Nature Structural and Molecular Biology, vol. 11, no. 4, pp. 380–381, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. D. Umeda, S. Yano, K. Yamada, and H. Tachibana, “Green tea polyphenol epigallocatechin-3-gallate signaling pathway through 67-kDa laminin receptor,” Journal of Biological Chemistry, vol. 283, no. 6, pp. 3050–3058, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. S. K. Patra, F. Rizzi, A. Silva, D. O. Rugina, and S. Bettuzzi, “Molecular targets of (-)-epigallocatechin-3-gallate (EGCG): specificity and interaction with membrane lipid rafts,” Journal of Physiology and Pharmacology, vol. 59, supplement 9, pp. 217–235, 2008. View at Google Scholar · View at Scopus
  49. X. Zhang, H. Zhang, M. Tighiouart et al., “Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor,” International Journal of Cancer, vol. 123, no. 5, pp. 1005–1014, 2008. View at Publisher · View at Google Scholar · View at Scopus